Increased vincristine neurotoxicity during treatment with itraconazole in 3 pediatric patients with acute myelogenous leukemia.

被引:0
|
作者
Muenchow, N [1 ]
Janka, G [1 ]
Erttmann, R [1 ]
Looft, G [1 ]
Bielack, S [1 ]
Winkler, K [1 ]
机构
[1] Univ Hamburg Hosp, Dept Pediat Hematol & Oncol, D-2000 Hamburg, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
4253
引用
收藏
页码:234B / 234B
页数:1
相关论文
共 50 条
  • [1] Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia
    Jeng, MR
    Feusner, J
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2001, 18 (02) : 137 - 142
  • [2] Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia
    Lopez-Lopez, Elixabet
    Gutierrez-Camino, Angela
    Astigarraga, Itziar
    Navajas, Aurora
    Echebarria-Barona, Aizpea
    Garcia-Miguel, Purificacion
    Garcia de Andoin, Nagore
    Lobo, Carmen
    Guerra-Merino, Isabel
    Martin-Guerrero, Idoia
    Garcia-Orad, Africa
    PHARMACOGENOMICS, 2016, 17 (07) : 731 - 741
  • [3] Infusional etoposide, daunorubicin, vincristine, and cytarabine in relapsed acute myelogenous leukemia.
    Walker, B
    Elkins, S
    Bigelow, C
    Files, J
    JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S289 - S289
  • [4] INCREASED HLA HOMOZYGOSITY IN LYMPHOMA BUT NOT IN ACUTE MYELOGENOUS LEUKEMIA.
    Crow, Danielle R.
    Aubrey, Michael T.
    Freed, Brian M.
    HUMAN IMMUNOLOGY, 2015, 76 : 23 - 23
  • [5] Prophylactic antibiotics reduce morbidity from septicemia during intensive treatment for pediatric acute myelogenous leukemia.
    Kurt, Beth
    Flynn, Patricia
    Shenep, Jerry
    Ribeiro, Raul
    Pui, Ching-Hon
    Lensing, Shelly
    Pounds, Stanley
    Razzouk, Bassem
    Rubriitz, Jeffrey
    BLOOD, 2006, 108 (11) : 543A - 544A
  • [6] Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients
    Renbarger, Jamie L.
    McCammack, Kevin C.
    Rouse, Caroline E.
    Hall, Stephen D.
    PEDIATRIC BLOOD & CANCER, 2008, 50 (04) : 769 - 771
  • [7] Down syndrome patients with relapsed acute myelogenous leukemia.
    Loew, TW
    Gamis, A
    Smith, FO
    Massey, GV
    Woods, WG
    Hilden, JM
    Lange, B
    Alonzo, TA
    Chang, M
    Gerbing, RB
    BLOOD, 2004, 104 (11) : 215B - 215B
  • [8] Management of primary and treatment-related acute myelogenous leukemia.
    Schaison, G
    Leblanc, T
    Auvrignon, A
    Baruchel, A
    Leverger, G
    ANNALES DE PEDIATRIE, 1998, 45 (04): : 235 - 245
  • [9] Azacitidine as induction therapy of elderly patients with acute myelogenous leukemia.
    Khan, Cyrus
    Rossetti, James M.
    Hilton, Christie
    Sadhashiv, Santhosh
    Khalid, Sanaullah
    Abid, Arifa
    Fischer, Victoria
    Fazal, Salman
    Sahovic, Entezam A.
    Shadduck, Richard K.
    Lister, John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Significance of marrow angiogenesis factors in patients with acute myelogenous leukemia.
    Lin, Liang-In
    Lee, Cheng-Yeh
    Hu, Chung-Yi
    Tang, Jih-Luh
    Tien, Hwei Fang
    BLOOD, 2006, 108 (11) : 184B - 184B